SCHEMBL2881659

SCHEMBL2881659

CC(C)(C)OC(=O)NC1CCN(c2ccc(Oc3ccccc3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.55
SKP1 P63208 1/20 0.55
SKP2 Q13309 1/20 0.55
BTK Q06187 4/20 0.52
KCNA3 P22001 1/20 0.51
GPR119 Q8TDV5 1/20 0.50
KDM1A O60341 1/20 0.49
MAOB P27338 1/20 0.49
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DRD2 P14416 2/20 0.47
ME3 Q16798 1/20 0.46
CHRM4 P08173 1/20 0.46
NAMPT P43490 1/20 0.46
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
EPHX2 P34913 1/20 0.46
PIM1 P11309 1/20 0.46
PIM3 Q86V86 1/20 0.46
PIM2 Q9P1W9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830852 0.90 CKS1B (0.61) CKS1BSKP1SKP2KCNA3GPR119
SCHEMBL17557723 0.86 MAPT (0.56) CKS1BSKP1SKP2KCNA3GPR119
SCHEMBL12321963 0.85 CKS1B (0.53) CKS1BSKP1SKP2KCNA3GPR119
SCHEMBL383106 0.84 USP2 (0.56) CKS1BSKP1SKP2KCNA3GPR119
SCHEMBL2883836 0.84 DRD2 (0.53) CKS1BSKP1SKP2DRD2ME3
SCHEMBL3130708 0.84 CKS1B (0.52) CKS1BSKP1SKP2KCNA3GPR119
SCHEMBL32665409 0.84 ME3 (0.54) CKS1BSKP1SKP2KCNA3GPR119
SCHEMBL22816546 0.83 CHRM4 (0.56) CKS1BSKP1SKP2GPR119CHRM4
SCHEMBL20968969 0.83 CKS1B (0.52) CKS1BSKP1SKP2BTKKCNA3
SCHEMBL23500781 0.83 CKS1B (0.56) CKS1BSKP1SKP2BTKKCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750012-B2 Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2010-07-06 US disclosed
US-7750012-B2 Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2010-07-06 US disclosed
US-7750012-B2 Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2010-07-06 US disclosed
EP-1968961-A2 BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION Decode Genetics EHF (IS) 2008-09-17 EP disclosed
WO-2007078335-A2 BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF. (IS) 2007-07-12 WO disclosed
WO-2007078335-A2 BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF. (IS) 2007-07-12 WO disclosed
US-20070149544-A1 BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-06-28 US disclosed
US-20070149544-A1 BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-06-28 US disclosed
US-20070149544-A1 BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149544-A1 BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTC4S, LTB4R CKS1B 2788/4885SKP1 2712/4885SKP2 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.